The Technical Analyst
Werewolf Therapeutics, [HOWL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Werewolf Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.78% $6.39
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 273.09 mill |
| EPS: | -1.050 |
| P/E: | -6.09 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 42.74 mill |
| Avg Daily Volume: | 0.251 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.09 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.04x |
| Company: PE -6.09 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.06 (-36.39%) $-2.33 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 5.93 - 6.86 ( +/- 7.28%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-04 | Atkins Michael B. | Buy | 35 000 | Stock Option (right to buy) |
| 2024-01-04 | Atkins Michael B. | Sell | 0 | Common Stock |
| 2024-01-02 | Trost Timothy W. | Buy | 150 000 | Stock Option (right to buy) |
| 2024-01-02 | Lubman Ellen | Buy | 131 900 | Stock Option (right to buy) |
| 2024-01-02 | Isaacs Randi | Buy | 200 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 99.28 |
| Last 97 transactions |
| Buy: 45 258 272 | Sell: 143 550 934 |
Forecast:
16:00 - $6.39
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.39
Forecast 2: 16:00 - $6.39
Forecast 3: 16:00 - $6.39
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.39 (-0.78% ) |
| Volume | 0.0817 mill |
| Avg. Vol. | 0.251 mill |
| % of Avg. Vol | 32.59 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HOWL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $7.05 | N/A | Active |
|---|
HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-24 10:05:00 - Press Release
Werewolf Therapeutics Announces Wtx-124 Clinical Abstract Accepted For Presentation At The 2024 American Society Of Clinical Oncology (asco) Annual Meeting
Company to present an update of its ongoing monotherapy and combination phase 1/1b study of wtx-124 in advanced or metastatic solid tumors
2024-04-23 08:00:00 - Press Release
Werewolf Therapeutics Presents First Preclinical Data Highlighting Il-10 Indukine Molecules As A Potential Therapy For Inflammatory Bowel Disease (ibd) At Aai Annual Meeting
First data demonstrating application of predator™ platform in immune-mediated diseases watertown, mass., april 23, 2024 (globe newswire) -- werewolf therapeutics, inc. (the “company” or “werewolf”) (nasdaq: howl) today announced a poster presenting preclinical data characterizing conditionally-activated il-10 indukine molecules for the treatment of colitis in animal models, a novel approach leveraging its predator™ protein engineering platform, at immunologytm 2024, the annual meeting of the american association of immunologists (aai) taking place may 3-7 in chicago, illinois.
2024-04-05 16:30:00 - Press Release
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-tumor Effects Of Pro-inflammatory Cytokine Therapeutics Wtx-518 And Wtx-712 At Aacr 2024 Annual Meeting
Wtx-518, a conditionally activated il-18 indukine tm molecule that resists suppression by il-18bp, led to complete tumor regressions in preclinical models
2024-04-04 16:30:00 - Press Release
Werewolf Therapeutics To Present First-of-its-kind Data Demonstrating Utility For Predator™ Platform In Immunology-based Diseases At Aai Annual Meeting
Predator protein engineering technology allows for the expansion of indukine™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease predator protein engineering technology allows for the expansion of indukine™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease
2024-03-07 07:00:00 - Press Release
Werewolf Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
– additional monotherapy dose-escalation data from ongoing phase 1/1b clinical trial of wtx-124 expected to be presented in the first half of 2024 –
Latest News
2024-04-15 13:01:06 - Zacks Investment Research
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-04-04 16:30:00 - GlobeNewsWire
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease
2024-03-12 10:55:16 - Zacks Investment Research
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-03-07 09:46:04 - Zacks Investment Research
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.
2023-11-06 17:14:34 - Seeking Alpha
Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days
Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of IL-2 selectively near the tumor, minimizing toxicity. Early data from phase 1 trials showed remarkable tolerability and PK/PD, as well as the faintest signals of efficacy.
2023-11-03 10:26:42 - InvestorPlace
Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?
Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This clinical trial is ongoing and has the company treating patients with advanced or metastatic solid tumors with its interleukin 2 INDUKINE molecule.
2023-09-05 16:05:00 - GlobeNewsWire
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will participate in the following upcoming investor conferences in the month of September:
2023-08-25 16:48:46 - Seeking Alpha
Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets
Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of patients with solid tumors, expected Q4 of 2023. Another INDUKINE molecule being developed in the pipeline would be WTX-330, which is being advanced in a phase 1 open-label study treating patients with metastatic solid tumors and non-Hodgkin lymphoma. Werewolf has a collaboration agreement with Jazz Pharmaceuticals for the development of JZP898, an interferon alpha INDUKINE molecule, with potential milestone payments of up to $1.26 billion.
2023-08-10 10:01:02 - Zacks Investment Research
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.53 per share a year ago.
2023-07-26 08:40:33 - Zacks Investment Research
New Strong Buy Stocks for July 26th
ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.